The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule

• Main Authors: Xuhui Shen, Fugen Yin
• Format: Article
• Language: English
• Published: Elsevier 2021-10-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Lianhua-Qingwen capsule; SARS-COV-2; SARS; Broad-spectrum antiviral
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332221007812

Lianhua-Qingwen capsule (LQC) is a commonly used Traditional Chinese Medicine (TCM) in China and has 11 herb components. The main active ingredient can target specific molecules and perform many clinic treatment roles. LQC has been authorized by National Medical Products Administration (NMPA) of China to treat severe acute respiratory syndrome (SARS) in 2002–2003, type A influenza virus HIN1 pandemic in 2009, H7N9, H3N2 and coronavirus disease-19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in 2020. It is also widely used to treat common cold with wind-heat syndrome, chronic rhinosinusitis (CRS), amygdalitis and chronic obstructive pulmonary disease. This article summarizes the advanced research progress of LQC in clinical application, mechanisms and provides new clues in the clinical application of LQC.